Biotech Industry Forms International Council - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biotech Industry Forms International Council


The Biotechnology Industry Organization (BIO) is reporting that an international confederation of biotechnology trade associations has created the International Council on Biotechnology Associations (ICBA) to advocate for public policies that support worldwide biotechnology growth. BIO’s president and CEO, Jim Greenwood, has been elected to serve as ICBA Chairman, and Nathalie Moll, secretary general of EuropaBio, was elected Vice Chair.

“The increasingly global biotechnology industry provides breakthrough products and technologies that combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes,” said Greenwood in a press release. “However, the biotechnology sector faces both challenges and opportunities that cross borders.  In forming the ICBA, our industry is taking an important step that allows us to better coordinate, organize and face these issues around the world together."

“Biotechnology is geared at enhancing our quality of life and responding to society’s grand challenges such as an ageing and ever increasing population, healthcare choice and affordability, resource efficiency, food security, climate change, energy shortages and economic growth,” said Moll in the press release. “The ICBA will advocate for more efficient and effective governance, science-based regulatory systems and the right framework conditions for competitiveness and innovation to ensure faster and more equitable access to biotech products and processes for patients, farmers and consumers around the world.”

Source: BIO.org

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here